C84.63 Anaplastic large cell lymphoma, ALK-positive, intra-abdominal lymph nodes

Name of the Condition

• Anaplastic large cell lymphoma, ALK-positive, intra-abdominal lymph nodes (ICD-10 Code: C84.63)

Summary

Anaplastic large cell lymphoma, ALK-positive, intra-abdominal lymph nodes (ALCL, ALK-positive) is a rare subtype of non-Hodgkin lymphoma that primarily affects T-lymphocytes. It is characterized by the presence of the anaplastic lymphoma kinase (ALK) protein, resulting from a specific genetic rearrangement. This condition typically presents as a rapidly growing tumor involving the intra-abdominal lymph nodes. ALCL, ALK-positive is more common in children and young adults and is generally considered aggressive but responsive to targeted therapies.

Causes

The exact cause of ALK-positive ALCL is not fully understood. The disease is driven by a genetic translocation involving the ALK gene, most commonly the t(2;5)(p23;q35) translocation, which results in overexpression of the ALK protein. This abnormal protein promotes uncontrolled cell growth and survival. While the translocation is a key driver, other genetic mutations may contribute to disease development, though specific environmental triggers remain unclear.

Risk Factors

• Age: More common in children and young adults, with a peak incidence in the second and third decades of life.
• Gender: Slightly higher prevalence in males.
• Genetic factors: Presence of the ALK translocation is a primary risk factor.
• Immunosuppression: Weakened immune systems may increase risk.

Symptoms

• Painless swelling of intra-abdominal lymph nodes.
• Abdominal pain or discomfort.
• Unexplained weight loss.
• Fever, night sweats, or fatigue.
• Loss of appetite.

Diagnosis

Diagnosis involves a combination of clinical evaluation, imaging studies (e.g., CT or MRI of the abdomen), and biopsy of the affected lymph nodes. Histopathological examination confirms the presence of large, anaplastic cells, and immunohistochemistry or molecular testing verifies ALK positivity. Staging may include additional tests to assess disease spread.

Treatment Options

Treatment typically includes systemic therapy such as chemotherapy, often combined with targeted therapies like ALK inhibitors. Radiation therapy may be used for localized disease. Treatment plans are tailored to the patient’s age, overall health, and disease extent, with options including clinical trials for advanced cases.

Prognosis and Follow-Up

Prognosis varies based on disease stage, response to treatment, and individual factors. ALK-positive ALCL generally has a better prognosis than ALK-negative subtypes, especially in younger patients. Follow-up involves regular monitoring with imaging and clinical assessments to detect recurrence or complications.

Complications

• Disease progression or recurrence.
• Treatment-related side effects (e.g., infection, organ toxicity).
• Metastasis to other organs.
• Long-term effects of therapy, such as secondary malignancies.

Lifestyle & Prevention

• Maintain a healthy immune system through balanced nutrition and regular exercise.
• Avoid known carcinogens (e.g., tobacco, excessive alcohol).
• Follow recommended cancer screening guidelines.
• Seek prompt medical attention for persistent symptoms.

When to Seek Professional Help

Consult a healthcare provider if you experience persistent abdominal swelling, unexplained weight loss, fever, or other concerning symptoms. Early evaluation is critical for timely diagnosis and treatment.

Tips for Medical Coders

• Use C84.63 for ALK-positive anaplastic large cell lymphoma specifically involving intra-abdominal lymph nodes.
• Ensure documentation supports the anatomical site (intra-abdominal lymph nodes) to justify code assignment.
• Verify ALK positivity through laboratory or pathology reports to confirm the subtype.
• Differentiate from other lymphoma codes based on site and molecular markers.